← Back
NeuroTrials.ai
Neurology Clinical Trial Database

HARMONY

Trial of Pimavanserin in Dementia-Related Psychosis

Year of Publication: 2021

Authors: Pierre N. Tariot, Jeffrey L. Cummings, Maria E. Soto-Martin, ..., Erin P. Foff

Journal: New England Journal of Medicine

Citation: N Engl J Med 2021;385:309-19

Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2034634


Clinical Question

Does continuation of pimavanserin reduce relapse of psychosis compared with discontinuation (switch to placebo) in patients with dementia-related psychosis who had an initial response to open-label pimavanserin?

Bottom Line

In patients with dementia-related psychosis who responded to open-label pimavanserin, continuation of treatment significantly reduced relapse of psychosis compared with discontinuation (13% vs 28%, HR 0.35). The trial was stopped early for efficacy. Pimavanserin did not worsen cognition or motor function.

Major Points

  • Randomized discontinuation design: 12-week open-label phase followed by double-blind randomization of responders to continue pimavanserin or switch to placebo
  • 61.8% of eligible patients (217/351) met sustained response criteria at weeks 8 and 12 and were randomized
  • Relapse occurred in 13% of pimavanserin group vs 28% of placebo group (HR 0.35, P=0.005)
  • Trial stopped early at interim analysis when P<0.0066 threshold was met
  • 66.3% had Alzheimer's disease, 15.1% Parkinson's disease dementia, 9.7% vascular dementia, 7.1% DLB, 1.8% FTD
  • Mean MMSE score improved by 1.0 point during open-label phase and was maintained with continued pimavanserin
  • No worsening of extrapyramidal symptoms (ESRS-A score improved with pimavanserin)
  • Pimavanserin acts via selective 5-HT2A inverse agonism without D2 dopamine receptor binding

Design

Study Type: Phase 3, multicenter, randomized, double-blind, placebo-controlled discontinuation trial

Randomization: 1

Blinding: Double-blind after randomization; investigators, site staff, adjudication committee, and sponsor personnel unaware of assignments

Enrollment Period: August 2017 - October 2019

Follow-up Duration: Up to 26 weeks double-blind phase (plus 4-week safety follow-up)

Centers: 101

Countries: United States, Canada, Eastern Europe, Western Europe, Latin America

Sample Size: 392

Analysis: Cox regression model with covariates for trial-group assignment, dementia strata, and geographic region; robust sandwich variance-type estimator; hierarchical testing at P<0.0066


Inclusion Criteria

  • Age 50 to 90 years
  • Dementia diagnosis meeting NIA-AA criteria
  • Clinical criteria for one or more: Parkinson's disease dementia, dementia with Lewy bodies, Alzheimer's disease, frontotemporal dementia, or vascular dementia
  • MMSE score 6 to 24
  • Psychotic symptoms for at least 2 months
  • Care partner able to reliably report symptoms
  • SAPS-H+D total score ≥10 at screening and baseline
  • SAPS-H+D global rating subscore ≥4
  • CGI-Severity score ≥4

Exclusion Criteria

  • Unstable use of acetylcholinesterase inhibitors or memantine (must be stable for 12 weeks)
  • Use of antipsychotics within 2 weeks or 5 half-lives before baseline

Arms

FieldOpen-Label PimavanserinDouble-Blind PimavanserinControl
InterventionPimavanserin 34 mg once daily (dose reduction to 20 mg permitted weeks 1-4 for tolerability)Continue pimavanserin at final open-label dose (34 mg or 20 mg once daily)Switch from pimavanserin to matching placebo
Duration12 weeksUp to 26 weeksUp to 26 weeks

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Time from randomization to relapse of psychosis (defined as: ≥30% increase in SAPS-H+D and CGI-I 6 or 7, OR hospitalization for dementia-related psychosis, OR stopping trial/withdrawal for lack of efficacy, OR use of other antipsychotics)Primary28 of 99 (28%)12 of 95 (13%)0.350.005
Time to trial discontinuation for any reasonSecondary38 of 99 (38%)21 of 95 (22%)0.450.005
SAPS-H+D change during open-label phase (week 12)Secondary
MMSE change during open-label phaseSecondary
MMSE change at 38 weeks (full trial)Secondary
ESRS-A change during open-label phaseSecondary
ESRS-A change at 26 weeks double-blindSecondary−0.4 ± 0.3−0.9 ± 0.6
Any adverse event - Open-labelAdverse
Any adverse event - Double-blindAdverse41 (36.6%)43 (41.0%)
Serious adverse event - Open-labelAdverse
Serious adverse event - Double-blindAdverse4 (3.6%)5 (4.8%)
Death - Open-labelAdverse
Death - Double-blindAdverse01 (1.0%) - septic encephalopathy from dental abscess, unrelated
Headache - Double-blindAdverse5 (4.5%)10 (9.5%)
Urinary tract infection - Double-blindAdverse4 (3.6%)7 (6.7%)
Constipation - Open-labelAdverse
QT prolongation (asymptomatic) - All pimavanserin exposureAdverse
Mean QTcF prolongation - Open-labelAdverse

Subgroup Analysis

Approximately 15% of patients had Parkinson's disease dementia (for which pimavanserin is already FDA-approved for psychosis). 61% of PD patients in this trial had moderate-to-severe dementia (MMSE <21), unlike previous PD psychosis trials that included only cognitively normal or mildly impaired patients.


Criticisms

  • Randomized discontinuation design selects for responders, limiting ability to assess response in initial non-responders
  • Trial stopped early for efficacy, limiting assessment of clinical predictors of relapse and long-term safety
  • ~15% of patients had Parkinson's disease (for which pimavanserin is already approved), potentially biasing results
  • Almost all patients were White (96.6%), limiting generalizability
  • Median double-blind exposure was only ~18 weeks (pimavanserin) and ~11 weeks (placebo) due to early stopping
  • Response criteria required sustained response at both weeks 8 and 12, excluding late responders
  • QT prolongation is a known class concern; mean 5.4 msec increase observed
  • Brief psychosocial therapy during screening may have contributed to improvement

Funding

Acadia Pharmaceuticals

Based on: HARMONY (New England Journal of Medicine, 2021)

Authors: Pierre N. Tariot, Jeffrey L. Cummings, Maria E. Soto-Martin, ..., Erin P. Foff

Citation: N Engl J Med 2021;385:309-19

Content summarized and formatted by NeuroTrials.ai.